Compare GLRE & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLRE | DCTH |
|---|---|---|
| Founded | 2004 | 1988 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 501.7M | 578.4M |
| IPO Year | 2007 | 2015 |
| Metric | GLRE | DCTH |
|---|---|---|
| Price | $14.83 | $15.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | 117.3K | ★ 309.5K |
| Earning Date | 11-02-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 75.00 | ★ 107.53 |
| EPS | ★ 0.18 | 0.04 |
| Revenue | ★ $729,777,000.00 | N/A |
| Revenue This Year | N/A | $24.61 |
| Revenue Next Year | N/A | $24.27 |
| P/E Ratio | ★ $81.89 | $396.75 |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $8.12 |
| 52 Week High | $19.39 | $17.42 |
| Indicator | GLRE | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 44.30 |
| Support Level | $14.62 | $9.98 |
| Resistance Level | $15.31 | $16.51 |
| Average True Range (ATR) | 0.31 | 0.48 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 60.75 | 28.81 |
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.